- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01324830
Monotherapy Dose Finding With BI 847325 in Solid Tumours
An Open Label Phase Ia/Ib Study of Two Dosing Schedules of BI 847325, Orally Administered Once a Day in Patients With Advanced Solid Tumours, With Repeated Cyclic Administration in Patients With Clinical Benefit
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Bruxelles, Belgium
- 1287.1.3201 Boehringer Ingelheim Investigational Site
-
Leuven, Belgium
- 1287.1.3202 Boehringer Ingelheim Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Patients with a histologically or cytologically confirmed diagnosis of an advanced unresectable and/or metastatic solid tumour, and who have failed conventional treatment or for whom no therapy of proven efficacy exists or who are not amenable to standard therapies.
- Age 18 years and older
- Written informed consent consistent with International conference on harmonization - Good clinical practice (ICH-GCP) and local legislation
- Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.
- Recovery of therapy-related toxicities from previous anti-tumour therapies to Common Terminology Criteria for Adverse Events (CTCAE) = grade 1 (with the exception of alopecia).
- Written informed consent to the use of archival tumour sample for determination of the BRAF/Tat sarcoma viral oncogene homolog (RAS) mutational status.
- Life expectancy of at least 12 weeks.
In escalation phase, when pharmacokinetic (PK) close to predicted Cmax or when signs of progressive disease (PD) modulation present, optional tumour biopsies (at same timepoints as in expansion phase) for the patients who consented to it.
In addition, all patients included in the expansion phase (part Ib) must:
- have been diagnosed with one of the following tumours: melanoma, colorectal carcinoma, Non Small Cell Lung Cancer (NSCLC) or exocrine pancreas adenocarcinoma, and have been shown on their archival tumour sample to have KRAS or BRAF mutation.
- have a measurable disease.
- have documented/proven progressive disease within the last 6 months, according to Response Evaluation Criteria In Solid Tumours (RECIST) criteria
11. have a tumour lesion accessible for biopsies (pre- and post-treatment): this is mandatory for patients with colorectal carcinoma or melanoma, optional for patients with NSCLC or exocrine pancreas adenocarcinoma.
Exclusion criteria:
- Inability to swallow tablets.
- Additional other serious illness , concomitant non-oncological disease (e.g. active infectious disease or known chronic Hepatitis B/Hepatitis C infection and HIV), or ongoing toxicity from prior therapies considered by the investigator to potentially compromise patient's safety in this trial.
- Clinical evidence of symptomatic progressive brain or leptomeningeal disease during the last 28 days.
- Second malignancy currently requiring another anti-cancer therapy.
- Absolute neutrophil count less than 1500/mm3.
- Platelet count less than 100 000/mm3.
- Bilirubin greater than 1.5 mg/dL (>26 µmol/L, Système international (SI) unit equivalent) (except known Gilbert's syndrome).
- Aspartate amino transferase (AST) and/or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal (if related to liver metastases, greater than five times the upper limit of normal).
- Serum creatinine greater than 1.5 mg/dL (>132 µmol/L, SI unit equivalent).
- Previous episode of QT prolongation due to a medication which, as a result of it, had to be discontinued; or long QT syndrome; or corrected QT interval (QTc) with Fridericia's correction >480 msec on screening ECG.
- Pregnancy or breastfeeding.
- Women or men who are sexually active and unwilling to use a medically acceptable method of contraception.
- Treatment with other investigational drugs or participation in another clinical interventional trial within the past four weeks before start of therapy or concomitant with this trial.
- Systemic anti-cancer therapy or radiotherapy within the past four weeks before start of therapy or concomitantly with this trial. This restriction does not apply to Luteinizing hormone-releasing hormone (LHRH) agonists, steroids and bisphosphonates.
- Patients unable to comply with the protocol.
- Active alcohol or drug abuse.
- history or presence of cardiovascular abnormalities deemed clinically relevant by the investigator. Myocardial infarction within 6 months prior to study.
- Cardiac left ventricular ejection fraction <50% or less than institutional lower limit of normal by Multiple Gated Acquisition scan (MUGA) or echocardiography
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: arm A
14 days once a day oral intake of BI 847325 followed by 7 days break in 3-week cycles
|
low to high dose
|
Experimental: arm B
5 days once daily oral intake of BI 847325 followed by 2 days break, repeated every week
|
low to high dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Patients With Dose Limiting Toxicity During the First Treatment Cycle in Phase Ia Part of the Study
Time Frame: 3 weeks
|
Occurrence of dose limiting toxicity (DLT) during the first treatment cycle for the treatment Schedules A and B. Some patients excluded from Treated Set (TS) as they were not evaluable for determination of maximum tolerated dose. Thus the number of evaluable TS patients are not the same as the number of original TS patients. |
3 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best Overall Response
Time Frame: From the start of treatment until the last evaluable assessment. The data cut-off date is 29-Nov-2013
|
Best overall response was the best response a patient experienced during their time on study from the start of treatment until: disease progression, the last evaluable assessment in the absence of progression, or the start of subsequent anti-cancer therapy.
Death was not considered as progressive disease when determining best overall response; patients who died prior to an evaluable imaging assessment were reported as not evaluable.
Some patients were excluded from TS as they were not evaluable for determination of maximum tolerated dose.
Thus the number of evaluable TS patients are not the same as the number of original TS patients.
|
From the start of treatment until the last evaluable assessment. The data cut-off date is 29-Nov-2013
|
Objective Response
Time Frame: From the start of treatment and the earliest of disease progression, death, or the end of treatment. The data cut-off date is 29-Nov-2013.
|
Objective response was a best overall response of complete or partial response, recorded between the start of treatment and the earliest of disease progression, death, or the end of treatment. Some patients excluded from TS as they were not evaluable for determination of maximum tolerated dose. Thus the number of evaluable TS patients are not the same as the number of original TS patients. |
From the start of treatment and the earliest of disease progression, death, or the end of treatment. The data cut-off date is 29-Nov-2013.
|
Disease Control
Time Frame: From the start of treatment to the earliest of disease progression, death, or the end of treatment. The data cut-off date is 29-Nov-2013.
|
Disease control was a best overall response of complete response, partial response or stable disease, recorded between the start of treatment and the earliest of disease progression, death, or the end of treatment.
Some patients excluded from TS as they were not evaluable for determination of maximum tolerated dose.
Thus the number of evaluable TS patients are not the same as the number of original TS patients.
|
From the start of treatment to the earliest of disease progression, death, or the end of treatment. The data cut-off date is 29-Nov-2013.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 1287.1
- 2010-023832-18 (EudraCT Number: EudraCT)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
GlaxoSmithKlineCompleted
-
John M. BuattiNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedUterine Cervical Neoplasms | Prostatic Neoplasms | Rectal Neoplasms | Endometrial Neoplasms | Anus NeoplasmsUnited States
-
Amphia HospitalRecruitingColonic Neoplasms MalignantNetherlands
-
GlaxoSmithKlineRecruitingColonic Neoplasms | Neoplasms, ColonUnited States, Finland, France, Italy, Japan, Netherlands, Norway, Spain, Taiwan, United Kingdom, Australia, Belgium, Brazil, Germany, Greece, Sweden, Turkey, Canada, Korea, Republic of, Argentina, Hungary, Estonia, Portugal, Mexico, Pa...
-
Marquette General Health SystemUpper Michigan Brain Tumor CenterWithdrawnGlioma | MeningiomaUnited States
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain StemUnited States
-
GlaxoSmithKlineRecruitingNeoplasms, RectalUnited States, France, Italy, Japan, Spain, United Kingdom, Germany, Korea, Republic of, Canada, Netherlands
-
Russian Society of Colorectal SurgeonsRecruitingNeoplasms,ColorectalRussian Federation
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
Novartis PharmaceuticalsBayerCompletedColorectal Neoplasms | Rectal Neoplasms | Colonic NeoplasmsUnited States, Germany, Belgium, Canada, Spain, United Kingdom, Taiwan, France, Switzerland, Sweden, Portugal, New Zealand, Italy, Slovakia, Australia, Austria, Brazil, Hong Kong
Clinical Trials on day 1 to day 14
-
Alexandra Hospital, Athens, GreeceHellenic Society of GastroenterologyCompletedH.Pylori Infection | H.Pylori Gastrointestinal Disease | H. Pylori Associated Phlegmonous GastritisGreece
-
PfizerCompleted
-
Northwestern UniversityCompleted
-
Robert Jones and Agnes Hunt Orthopaedic and District...Smith & Nephew, Inc.Recruiting
-
Pierre Fabre MedicamentCompletedMalignant Neoplasm of BreastChina, Taiwan, Singapore
-
Centre hospitalier de l'Université de Montréal...CompletedPneumonia | Acute Respiratory Distress Syndrome | Pulmonary Embolism | Dyspnea | Hypoxemia | AtelectasisCanada
-
Makerere UniversityMbarara University of Science and Technology; Ministry of Health, Uganda; Joint...Not yet recruiting
-
Universitaire Ziekenhuizen KU LeuvenRecruitingMitral Valve Prolapse | Ventricular ArrythmiaBelgium
-
Amphivena Therapeutics, Inc.CompletedMyelodysplastic Syndrome (MDS)United States
-
EngenderHealthUnited States Agency for International Development (USAID); World Health OrganizationCompletedVaginal FistulaKenya, Ethiopia, Congo, The Democratic Republic of the, Guinea, Nigeria, Niger, Sierra Leone, Uganda